|
Gene: DUSP2 |
Gene summary for DUSP2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | DUSP2 | Gene ID | 1844 |
Gene name | dual specificity phosphatase 2 | |
Gene Alias | PAC-1 | |
Cytomap | 2q11.2 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q05923 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1844 | DUSP2 | HSIL_HPV_1 | Human | Cervix | HSIL_HPV | 3.26e-06 | -4.81e-01 | 0.0116 |
1844 | DUSP2 | HSIL_HPV_2 | Human | Cervix | HSIL_HPV | 2.25e-16 | -5.47e-01 | 0.0208 |
1844 | DUSP2 | N_HPV_2 | Human | Cervix | N_HPV | 1.54e-06 | 2.16e-01 | -0.0131 |
1844 | DUSP2 | CCI_1 | Human | Cervix | CC | 1.38e-04 | -5.98e-01 | 0.528 |
1844 | DUSP2 | CCI_2 | Human | Cervix | CC | 4.51e-04 | -5.98e-01 | 0.5249 |
1844 | DUSP2 | CCI_3 | Human | Cervix | CC | 1.19e-06 | -5.98e-01 | 0.516 |
1844 | DUSP2 | CCII_1 | Human | Cervix | CC | 3.49e-06 | -5.64e-01 | 0.3249 |
1844 | DUSP2 | Tumor | Human | Cervix | CC | 2.65e-13 | -5.43e-01 | 0.1241 |
1844 | DUSP2 | sample3 | Human | Cervix | CC | 1.67e-17 | -5.40e-01 | 0.1387 |
1844 | DUSP2 | H2 | Human | Cervix | HSIL_HPV | 6.16e-09 | -4.62e-01 | 0.0632 |
1844 | DUSP2 | L1 | Human | Cervix | CC | 3.30e-04 | -4.86e-01 | 0.0802 |
1844 | DUSP2 | T3 | Human | Cervix | CC | 1.19e-13 | -5.14e-01 | 0.1389 |
1844 | DUSP2 | LZE20T | Human | Esophagus | ESCC | 7.26e-07 | 1.34e+00 | 0.0662 |
1844 | DUSP2 | LZE22T | Human | Esophagus | ESCC | 3.51e-08 | 2.06e+00 | 0.068 |
1844 | DUSP2 | LZE24D1 | Human | Esophagus | HGIN | 1.28e-05 | 1.62e+00 | 0.054 |
1844 | DUSP2 | LZE24T | Human | Esophagus | ESCC | 1.70e-08 | 9.14e-01 | 0.0596 |
1844 | DUSP2 | LZE21T | Human | Esophagus | ESCC | 3.65e-07 | 2.21e+00 | 0.0655 |
1844 | DUSP2 | LZE6T | Human | Esophagus | ESCC | 2.84e-03 | 8.90e-02 | 0.0845 |
1844 | DUSP2 | P1T-E | Human | Esophagus | ESCC | 1.14e-08 | 1.56e+00 | 0.0875 |
1844 | DUSP2 | P2T-E | Human | Esophagus | ESCC | 1.44e-48 | 2.09e+00 | 0.1177 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00507322 | Esophagus | ESCC | negative regulation of peptidyl-tyrosine phosphorylation | 42/8552 | 59/18723 | 6.35e-05 | 4.84e-04 | 42 |
GO:00610997 | Esophagus | ESCC | negative regulation of protein tyrosine kinase activity | 25/8552 | 31/18723 | 7.13e-05 | 5.38e-04 | 25 |
GO:00017064 | Esophagus | ESCC | endoderm formation | 38/8552 | 54/18723 | 2.08e-04 | 1.31e-03 | 38 |
GO:00017044 | Esophagus | ESCC | formation of primary germ layer | 75/8552 | 121/18723 | 2.17e-04 | 1.36e-03 | 75 |
GO:000717810 | Esophagus | ESCC | transmembrane receptor protein serine/threonine kinase signaling pathway | 195/8552 | 355/18723 | 2.58e-04 | 1.58e-03 | 195 |
GO:003432918 | Esophagus | ESCC | cell junction assembly | 227/8552 | 420/18723 | 3.06e-04 | 1.83e-03 | 227 |
GO:0043409110 | Esophagus | ESCC | negative regulation of MAPK cascade | 105/8552 | 180/18723 | 4.13e-04 | 2.35e-03 | 105 |
GO:00463289 | Esophagus | ESCC | regulation of JNK cascade | 80/8552 | 133/18723 | 5.35e-04 | 2.95e-03 | 80 |
GO:00182124 | Esophagus | ESCC | peptidyl-tyrosine modification | 202/8552 | 378/18723 | 1.34e-03 | 6.39e-03 | 202 |
GO:00181084 | Esophagus | ESCC | peptidyl-tyrosine phosphorylation | 200/8552 | 375/18723 | 1.60e-03 | 7.45e-03 | 200 |
GO:00507303 | Esophagus | ESCC | regulation of peptidyl-tyrosine phosphorylation | 144/8552 | 264/18723 | 2.22e-03 | 9.78e-03 | 144 |
GO:00610972 | Esophagus | ESCC | regulation of protein tyrosine kinase activity | 55/8552 | 90/18723 | 2.27e-03 | 9.99e-03 | 55 |
GO:00703046 | Esophagus | ESCC | positive regulation of stress-activated protein kinase signaling cascade | 74/8552 | 128/18723 | 3.77e-03 | 1.53e-02 | 74 |
GO:00328745 | Esophagus | ESCC | positive regulation of stress-activated MAPK cascade | 72/8552 | 126/18723 | 6.24e-03 | 2.29e-02 | 72 |
GO:00463302 | Esophagus | ESCC | positive regulation of JNK cascade | 52/8552 | 89/18723 | 1.04e-02 | 3.56e-02 | 52 |
GO:190188810 | Esophagus | ESCC | regulation of cell junction assembly | 109/8552 | 204/18723 | 1.53e-02 | 4.96e-02 | 109 |
GO:000647011 | Liver | Cirrhotic | protein dephosphorylation | 96/4634 | 281/18723 | 2.32e-04 | 2.11e-03 | 96 |
GO:001631111 | Liver | Cirrhotic | dephosphorylation | 130/4634 | 417/18723 | 1.58e-03 | 1.03e-02 | 130 |
GO:001056322 | Liver | HCC | negative regulation of phosphorus metabolic process | 259/7958 | 442/18723 | 4.29e-12 | 1.92e-10 | 259 |
GO:004593622 | Liver | HCC | negative regulation of phosphate metabolic process | 258/7958 | 441/18723 | 6.00e-12 | 2.60e-10 | 258 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa040109 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa0401012 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa0401014 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
hsa0401015 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
hsa0401023 | Oral cavity | EOLP | MAPK signaling pathway | 68/1218 | 302/8465 | 7.48e-05 | 3.40e-04 | 2.01e-04 | 68 |
hsa0401033 | Oral cavity | EOLP | MAPK signaling pathway | 68/1218 | 302/8465 | 7.48e-05 | 3.40e-04 | 2.01e-04 | 68 |
hsa0401010 | Prostate | BPH | MAPK signaling pathway | 87/1718 | 302/8465 | 2.05e-04 | 1.13e-03 | 6.98e-04 | 87 |
hsa0401013 | Prostate | BPH | MAPK signaling pathway | 87/1718 | 302/8465 | 2.05e-04 | 1.13e-03 | 6.98e-04 | 87 |
hsa0401022 | Prostate | Tumor | MAPK signaling pathway | 87/1791 | 302/8465 | 8.46e-04 | 3.94e-03 | 2.45e-03 | 87 |
hsa0401032 | Prostate | Tumor | MAPK signaling pathway | 87/1791 | 302/8465 | 8.46e-04 | 3.94e-03 | 2.45e-03 | 87 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DUSP2 | SNV | Missense_Mutation | novel | c.625N>C | p.Cys209Arg | p.C209R | Q05923 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
DUSP2 | SNV | Missense_Mutation | rs768360352 | c.878T>G | p.Val293Gly | p.V293G | Q05923 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
DUSP2 | SNV | Missense_Mutation | c.829N>T | p.Arg277Cys | p.R277C | Q05923 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
DUSP2 | SNV | Missense_Mutation | rs751919546 | c.619N>A | p.Ala207Thr | p.A207T | Q05923 | protein_coding | tolerated(0.18) | benign(0.397) | TCGA-NH-A50U-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Ancillary | leucovorin | PD |
DUSP2 | SNV | Missense_Mutation | novel | c.712N>A | p.Glu238Lys | p.E238K | Q05923 | protein_coding | deleterious(0) | possibly_damaging(0.869) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
DUSP2 | SNV | Missense_Mutation | novel | c.62N>A | p.Pro21Gln | p.P21Q | Q05923 | protein_coding | tolerated(0.31) | possibly_damaging(0.769) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DUSP2 | SNV | Missense_Mutation | novel | c.824N>A | p.Ser275Asn | p.S275N | Q05923 | protein_coding | deleterious(0.03) | benign(0.015) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
DUSP2 | SNV | Missense_Mutation | novel | c.721G>T | p.Gly241Cys | p.G241C | Q05923 | protein_coding | deleterious(0.04) | possibly_damaging(0.537) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
DUSP2 | SNV | Missense_Mutation | novel | c.16N>A | p.Ala6Thr | p.A6T | Q05923 | protein_coding | tolerated(0.3) | benign(0) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DUSP2 | SNV | Missense_Mutation | c.899T>G | p.Phe300Cys | p.F300C | Q05923 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-ES-A2HT-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |